Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

Sionna Therapeutics is a promising biotech company with a potential $4.3B peak sales franchise due to their focus on developing treatments that address underlying genetic mutations in cystic fibrosis. With novel candidates targeting CFTR stabilization and an upcoming Phase 2a trial, they have the potential to compete with established treatments and improve long-term outcomes for CF patients. However, there are risks associated with their approach and competition in the market.

Bears say

Sionna Therapeutics is facing several risks, including potential delays or failures in drug development and clinical studies, strong competition from Vertex Pharmaceuticals, the challenge of commercializing drugs for rare diseases, and the need for continued financial support until commercialization. Despite promising early data and the potential for differentiation in terms of efficacy, safety, and dosing convenience, Sionna's combination therapies will need to show superiority or at least non-inferiority to gain meaningful market share. Investors are waiting for data from two catalyst events in summer 2026 for the SION-719 Ph2a and SION-451 Ph1 HV trials.

SION has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 10 analysts, SION has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.